Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, Kingsbury LL, Fang M, Radich J, Little RF, Erba HP. Assouline S, et al. Among authors: othus m. Leuk Lymphoma. 2023 Feb;64(2):473-477. doi: 10.1080/10428194.2022.2148212. Epub 2022 Dec 14. Leuk Lymphoma. 2023. PMID: 36517990 Free PMC article. Clinical Trial. No abstract available.
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Ostronoff F, et al. Among authors: othus m. Leukemia. 2013 Jan;27(1):238-41. doi: 10.1038/leu.2012.168. Epub 2012 Jun 22. Leukemia. 2013. PMID: 22722750 Free PMC article. Clinical Trial. No abstract available.
The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia.
Roshal M, Chien S, Othus M, Wood BL, Fang M, Appelbaum FR, Estey EH, Papayannopoulou T, Becker PS. Roshal M, et al. Among authors: othus m. Leukemia. 2013 Mar;27(3):728-31. doi: 10.1038/leu.2012.217. Epub 2012 Jul 31. Leukemia. 2013. PMID: 22926686 Free PMC article. No abstract available.
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Walter RB, et al. Among authors: othus m. Blood. 2013 Mar 28;121(13):2424-31. doi: 10.1182/blood-2012-10-462440. Epub 2013 Jan 16. Blood. 2013. PMID: 23325837 Free PMC article.
210 results